Peering Into Viatris's Recent Short Interest - Viatris (NASDAQ:VTRS)
- On May 22, 2025, Berger Montague and co-counsel secured a $147 million judgment from a Philadelphia jury in a case against Biosense Webster involving anticompetitive practices.
- The verdict followed nearly six years of hard-fought litigation challenging Biosense Webster's 2016 policy restricting support to hospitals using only its catheters, creating a factual dispute over illegal tying.
- The jury unanimously returned the verdict after an eight-day trial and two hours of deliberation, with damages set to be trebled and a likely total judgment nearing half a billion dollars.
- Joshua Davis of Berger Montague described the verdict as a major win for Innovative Health and a meaningful advancement in addressing the increasing expenses of health care.
- This ruling underscores Berger Montague's long-standing role in precedent cases and may impact future antitrust enforcement in healthcare markets involving tied support services.
27 Articles
27 Articles
Berger Montague Wins $147 Million Antitrust Jury Verdict for Innovative Health
PHILADELPHIA, May 22, 2025 /PRNewswire/ -- Berger Montague, a national plaintiffs' law firm, is pleased to announce that it and co-counsel— Jeffrey Berhold, P.C.; Kellogg, Hansen, Todd, Figel & Frederick, PLLC; and Theodora Oringher P.C. —have won a $147 million…

Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors With Substantial Losses to Inquire About a Securities Fraud Class Action by June 3, 2025
PHILADELPHIA, May 21, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against VIATRIS INC. ("Viatris" or the "Company") (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024…
Coverage Details
Bias Distribution
- 58% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage